Paul is a leader in driving innovative drug discovery approaches. His work has shaped diverse platform approaches to develop microbiome drug candidates for the treatment of infectious diseases and inflammatory disorders. As Chief Scientific Adviser at OpenBiome Foundation, Paul is helping to drive our scientific impact and reach. As the former CSO at Artizan Biosciences Inc., he guided a novel platform approach for identifying and targeting pathogenic intestinal bacteria with a focus on inflammatory bowel disease. He also served as the Vice President of Infection Biology at AstraZeneca and as the Chief Scientific Officer for Antibacterial Research at Pfizer, leading discovery teams that produced eight drug development candidates, provided critical research support for several marketed antibiotics, and successfully advanced a novel oxazolidinone for tuberculosis into Phase II studies. Paul received his Ph.D. in microbiology and immunology from Albany Medical College and conducted post-doctoral studies at the National Institutes of Health. He has served as a member of the Institute of Medicine’s Forum on Microbial Threats and as an advisor to the Bill and Melinda Gates Foundation on tuberculosis research strategy.